Pfizer CFO Dave Denton stepping down in August 2026

1 hour ago 1

Cris Tolomia

Thu, June 18, 2026 astatine 7:30 AM CDT 2 min read

Dave Denton, Pfizer's main fiscal officer, is departing the pharmaceutical institution for a presumption successful user goods, with his past time acceptable for Aug. 15, Pfizer announced Thursday.

Stepping into the relation connected Aug. 16 volition beryllium Cecile Guegan, who presently holds the rubric of elder vice president of concern for Pfizer's planetary biopharmaceutical concern and volition service arsenic interim CFO portion the institution runs a hunt — some interior and outer — for a imperishable hire. Pfizer said the 2 executives volition collaborate during the handover period.

In a statement, Pfizer Chairman and CEO Albert Bourla credited Denton with guiding the institution done large acquisitions, including the buyouts of crab therapy institution Seagen, migraine drugmaker Biohaven, and obesity cause developer Metsera. "Dave has been a dependable and trusted steward of Pfizer's fiscal health, and we are grateful for his leadership," Bourla said.

Denton notified Pfizer of his determination connected June 16, according to an SEC filing. The filing stated that his departure is not related to the company's fiscal oregon operating results oregon to immoderate disagreements implicit financial, operational, accounting, oregon reporting policies.

Guegan joined Pfizer successful 2005 and has held her existent relation since 2022, the institution said. She antecedently served arsenic vice president of concern for probe and improvement and the concern bureau from 2020 to 2022, and played a relation successful integrating Seagen into Pfizer successful 2024. She holds a master's grade from Brest Business School.

Pfizer banal was down 1.6% successful premarket trading Thursday, according to CNBC.

Denton has been a salient dependable connected Pfizer's fiscal performance. When Pfizer reported first-quarter 2026 gross of $14.45 billion, a 5% year-over-year summation driven by maturation successful oncology and different precocious launched and acquired products, Denton pointed to 22% year-over-year operational gross maturation from launched and acquired products arsenic a peculiar highlight. The institution near its full-year 2026 gross guidance unchanged astatine $59.5 cardinal to $62.5 billion.

Read Entire Article